{"title":"和记黄埔医药与礼来合作推进fruquininib在中国的开发","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I10.1985","DOIUrl":null,"url":null,"abstract":"Hutchison MediPharma (HMP), the R&D division of the Chinese pharmaceutical and healthcare group Hutchison Chi-Med, has partnered with Eli Lilly for second time with a licensing, co-development and commercialisation agreement for its Phase II cancer drug fruquintinib (HMPL-013), a highly selective small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases with potential in the treatment of advanced refractory solid tumours. The two companies will share development costs in China, thus allowing HMP to expand the clinical programme for the drug to multiple tumour types.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hutchison MediPharma Partners with Eli Lilly to Advance Development of Fruquintinib in China\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I10.1985\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hutchison MediPharma (HMP), the R&D division of the Chinese pharmaceutical and healthcare group Hutchison Chi-Med, has partnered with Eli Lilly for second time with a licensing, co-development and commercialisation agreement for its Phase II cancer drug fruquintinib (HMPL-013), a highly selective small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases with potential in the treatment of advanced refractory solid tumours. The two companies will share development costs in China, thus allowing HMP to expand the clinical programme for the drug to multiple tumour types.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"16 2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I10.1985\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I10.1985","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
和黄和黄医药(HMP)是中国制药和医疗集团和黄和黄医药(Hutchison and - med)的研发部门，与礼来公司(Eli Lilly)第二次合作，就其II期抗癌药物fruquininib (HMPL-013)达成许可、共同开发和商业化协议。fruquininib是一种高选择性血管内皮生长因子(VEGF)受体酪氨酸激酶的小分子抑制剂，具有治疗晚期难治性实体肿瘤的潜力。这两家公司将分担在中国的开发成本，从而使HMP能够将该药的临床项目扩展到多种肿瘤类型。
Hutchison MediPharma Partners with Eli Lilly to Advance Development of Fruquintinib in China
Hutchison MediPharma (HMP), the R&D division of the Chinese pharmaceutical and healthcare group Hutchison Chi-Med, has partnered with Eli Lilly for second time with a licensing, co-development and commercialisation agreement for its Phase II cancer drug fruquintinib (HMPL-013), a highly selective small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases with potential in the treatment of advanced refractory solid tumours. The two companies will share development costs in China, thus allowing HMP to expand the clinical programme for the drug to multiple tumour types.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
